Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) has been invited to present at the prestigious DCNY Summit, taking place in Washington, DC on September 18, 2025, and in New York on September 22, 2025. The summit, co-hosted by the Alliance Indus Foundation and various international partners, brings together policymakers, investors, and corporate leaders.
During the event, Hemogenyx will showcase its clinical progress, including updates on its Phase I clinical trial of CAR-T cell therapy for acute myeloid leukemia (AML). The company will have the opportunity to engage with key stakeholders and potential investors, as the summit has previously helped participants secure significant growth capital.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) 猫 stata invitata a presentare al prestigioso DCNY Summit, che si svolger脿 a Washington, DC il 18 settembre 2025 e a New York il 22 settembre 2025. Il summit, co-organizzato dalla Alliance Indus Foundation e da vari partner internazionali, riunisce responsabili politici, investitori e dirigenti aziendali.
Durante l'evento Hemogenyx illustrer脿 i progressi clinici raggiunti, comprese le novit脿 sul trial clinico di Fase I della terapia CAR-T per la leucemia mieloide acuta (AML). La societ脿 avr脿 l'opportunit脿 di confrontarsi con stakeholder chiave e potenziali investitori: in passato il summit ha aiutato i partecipanti a ottenere capitali di crescita rilevanti.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) ha sido invitada a presentar en el prestigioso DCNY Summit, que se celebrar谩 en Washington, DC el 18 de septiembre de 2025 y en Nueva York el 22 de septiembre de 2025. La cumbre, coorganizada por la Alliance Indus Foundation y varios socios internacionales, re煤ne a responsables pol铆ticos, inversores y l铆deres empresariales.
Durante el evento, Hemogenyx mostrar谩 sus avances cl铆nicos, incluyendo actualizaciones sobre su ensayo cl铆nico de Fase I de la terapia CAR-T para la leucemia mieloide aguda (AML). La compa帽铆a tendr谩 la oportunidad de conectarse con los principales interesados y posibles inversores; en ediciones anteriores la cumbre ha ayudado a participantes a asegurar importantes fondos de crecimiento.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF)臧� 甓岇渼 鞛堧姅 DCNY Summit鞐� 齑堨箔霅橃柎 2025雲� 9鞗� 18鞚� 鞗岇嫳韯� DC鞕� 2025雲� 9鞗� 22鞚� 雺挫殨鞐愳劀 氚滍憸毳� 歆勴枆頃╇媹雼�. 鞚� 靹滊皨鞚� Alliance Indus Foundation瓿� 鞐煬 甑牅 韺岉姼雱堦皜 瓿惦彊 欤检禍頃橂┌ 鞝曥眳 鞛呾晥鞛�, 韴瀽鞛� 氚� 旮办梾 毽崝霌れ潉 頃滌瀽毽棎 氇潔雼堧嫟.
頄夓偓 旮瓣皠 霃欖晥 Hemogenyx電� 旮夓劚 瓿垬靹� 氚表槇氤�(AML) 雽�靸� CAR-T 靹疙彫旃橂鞚� 1靸� 鞛勳儊鞁滍棙 霌� 鞛勳儊 歆勴枆 靸來櫓鞚� 靻岅皽頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 欤检殧 鞚错暣甏�瓿勳瀽 氚� 鞛犾灛 韴瀽鞛愲摛瓿� 甑愲頃� 旮绊殞毳� 臧栮矊 霅� 瓴冹澊氅�, 瓿缄卑 鞚� 靹滊皨鞚� 彀戈皜鞛愲摛鞚� 靸侂嫻頃� 靹膘灔 鞛愱笀鞚� 鞙犾箻頃橂姅 雿� 霃勳泙鞚� 欷� 氚� 鞛堨姷雼堧嫟.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) a 茅t茅 invit茅e 脿 pr茅senter au prestigieux DCNY Summit, qui se tiendra 脿 Washington, DC le 18 septembre 2025 et 脿 New York le 22 septembre 2025. Le sommet, coparrain茅 par la Alliance Indus Foundation et plusieurs partenaires internationaux, rassemble des d茅cideurs politiques, des investisseurs et des dirigeants d'entreprise.
Lors de l'茅v茅nement, Hemogenyx pr茅sentera ses avanc茅es cliniques, y compris des mises 脿 jour sur son essai clinique de phase I de th茅rapie CAR鈥慣 pour la leuc茅mie my茅lo茂de aigu毛 (LMA). La soci茅t茅 aura l'occasion d'茅changer avec des parties prenantes cl茅s et des investisseurs potentiels ; par le pass茅, le sommet a aid茅 des participants 脿 obtenir des capitaux de croissance importants.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) wurde eingeladen, auf dem renommierten DCNY Summit zu pr盲sentieren, das am 18. September 2025 in Washington, DC und am 22. September 2025 in New York stattfindet. Der Gipfel, der von der Alliance Indus Foundation und verschiedenen internationalen Partnern mitveranstaltet wird, bringt politische Entscheidungstr盲ger, Investoren und Unternehmensleiter zusammen.
W盲hrend der Veranstaltung wird Hemogenyx seine klinischen Fortschritte vorstellen, einschlie脽lich Updates zu seiner Phase鈥慖鈥慡tudie zur CAR鈥慣鈥慫elltherapie bei akuter myeloischer Leuk盲mie (AML). Das Unternehmen erh盲lt die Gelegenheit, mit wichtigen Akteuren und potenziellen Investoren in Kontakt zu treten; in der Vergangenheit hat der Gipfel Teilnehmern geholfen, bedeutende Wachstumskapitalien zu sichern.
- None.
- None.
Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit
LONDON, UK / / September 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce that the Company has been invited to participate and present at the upcoming DCNY Summit, taking place in Washington, DC on 18 September 2025 and in New York on 22 September 2025.
The DCNY Summit is co-hosted by the Alliance Indus Foundation, together with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other international partners, and is designed as a high-level forum connecting Washington, DC and New York to bring together policymakers, investors, corporate leaders, and innovators.
Hemogenyx will present its clinical progress and pipeline as part of the Summit's curated company showcase. Previous Summit participants have successfully secured significant growth capital, underscoring the Summit's reputation as a catalyst for financing and partnerships.
Participation in the DCNY Summit provides Hemogenyx with a valuable platform to:
Highlight recent clinical milestones, including the ongoing Phase I clinical trial of its lead CAR-T cell therapy for acute myeloid leukemia (AML);
Showcase the Company's broader therapeutic pipeline to an audience of influential stakeholders;
Engage directly with investors, collaborators, and decision-makers at the intersection of science, healthcare, and finance.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are honored to have been invited to present Hemogenyx at the DCNY Summit. This prestigious event convenes a remarkable group of global investors, corporate leaders, and policymakers, and provides us with a unique opportunity to highlight our progress and to engage with those who can help accelerate our mission to transform the treatment of cancer."
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About DCNY Summit
The DCNY Summit () is an annual high-level forum connecting Washington, DC and New York to bring together policymakers, corporate leaders, investors, and innovators. It is co-hosted by the Alliance Indus Foundation in partnership with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other global organizations. The Summit serves as a platform for showcasing transformative companies, fostering international collaboration, and catalyzing financing and innovation across life sciences, healthcare, and technology sectors.
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit .
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original on ACCESS Newswire
FAQ
When and where will Hemogenyx Pharmaceuticals (HOPHF) present at the DCNY Summit 2025?
What will Hemogenyx Pharmaceuticals showcase at the DCNY Summit 2025?
Who are the co-hosts of the DCNY Summit 2025?
What is the significance of Hemogenyx's participation in the DCNY Summit?
